Holen Sie sich die Stockscreener-App
85.96
1.45%
1.23
Handel nachbörslich:
85.96
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000 - The Globe and Mail
Incyte stock price target raised to $76 from $68 at UBS on valuation - Investing.com
How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook - Yahoo Finance
How Incyte Corporation stock performs in rising dollar environment2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Will Incyte Corporation (ICY) stock see insider accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - newser.com
Incyte Corp. stock rises Monday, still underperforms market - MarketWatch
Using Python tools to backtest Incyte Corporation strategiesJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Can Incyte Corporation rally from current levelsQuarterly Risk Review & Daily Price Action Insights - newser.com
How Incyte Corporation stock responds to policy changes2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 - BioSpace
Incyte jumps amid takeover speculation - MSN
How Incyte Corporation stock compares to market leadersWeekly Trade Report & Weekly Hot Stock Watchlists - newser.com
Incyte (INCY) Announces Promising Study Results for Cancer Treatments - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock - MarketBeat
RBC Capital Remains a Hold on Incyte (INCY) - The Globe and Mail
What 14 Analyst Ratings Have To Say About Incyte - Benzinga
Sun Pharma Attacks Incyte Patents In Alopecia Drug Battle - Law360
INCY: JP Morgan Raises Price Target to $89, Maintains Neutral Ra - GuruFocus
Incyte (NASDAQ:INCY) Given Hold (C+) Rating at Weiss Ratings - MarketBeat
Incyte Corporation $INCY Shares Purchased by Shell Asset Management Co. - MarketBeat
Is Incyte Corporation stock a safe buy before earnings2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Incyte Faces Revenue Squeeze As Jakafi Patent Winds Down - Finimize
Incyte to Report Third Quarter Financial Results - Business Wire
Incyte stock rating downgraded to Perform by Oppenheimer - Investing.com
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Incyte Corporation (INCY) Appoints New Principal Financial Officer - GuruFocus
Is Incyte Corporation (ICY) stock a defensive play amid uncertaintyTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
How to use Fibonacci retracement on Incyte CorporationPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
Grimes & Company Inc. Has $12.26 Million Position in Incyte Corporation $INCY - MarketBeat
Price action breakdown for Incyte CorporationJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Legacy Trust Cuts Holdings in Incyte Corporation $INCY - MarketBeat
Published on: 2025-10-05 05:30:49 - newser.com
Why Incyte Corporation (ICY) stock is favored by hedge funds2025 Stock Rankings & Community Consensus Stock Picks - newser.com
How Incyte Corporation (ICY) stock reacts to stronger dollar2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Institutional scanner results for Incyte Corporation2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
Incyte Grants Equity Awards to New Chief Strategy Officer David Gardner - MyChesCo
Incyte Appoints Thomas Tray as Financial Officer - The Globe and Mail
Impact Investors Inc Has $209,000 Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (NASDAQ:INCY) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Will Incyte's (INCY) New Strategy Team and CALR Antibody Hopes Reshape Its Long-Term Story? - simplywall.st
Incyte appoints Thomas Tray as principal financial officer - StreetInsider
Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - MSN
Incyte (INCY) Is Up 5.7% After FDA Pediatric Opzelura Approval and Leadership Updates Has the Bull Case Changed? - simplywall.st
Incyte Names Dave Gardner Chief Strategy Officer Amid Leadership Transition - MyChesCo
Will Incyte Corporation stock outperform value stocksWeekly Gains Report & Community Consensus Trade Alerts - newser.com
Backtesting results for Incyte Corporation trading strategiesMarket Risk Summary & Community Consensus Picks - newser.com
Incyte Corporation stock hits 52-week high at 88.19 USD By Investing.com - Investing.com Australia
FDA Expands Approval of Incyte’s Opzelura to Treat Pediatric Atopic Dermatitis - MSN
Incyte Corporation stock hits 52-week high at 88.19 USD - Investing.com
Robeco Institutional Asset Management B.V. Has $162.51 Million Stock Position in Incyte Corporation $INCY - MarketBeat
2 Reasons to Like INCY and 1 to Stay Skeptical - The Globe and Mail
Lbp Am Sa Has $12.17 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Public Employees Retirement System of Ohio Buys 3,951 Shares of Incyte Corporation $INCY - MarketBeat
Poinciana Advisors Group LLC Makes New Investment in Incyte Corporation $INCY - MarketBeat
Patton Albertson Miller Group LLC Acquires 5,497 Shares of Incyte Corporation $INCY - MarketBeat
Patton Fund Management Inc. Takes $254,000 Position in Incyte Corporation $INCY - MarketBeat
5.15%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):